Heroin antinociception changed from mu to delta receptor in streptozotocin-treated mice

Japanese Journal of Pharmacology

Volumn 78, Issue 4, 1998, Pages 443-454

  Rady, Jodie J ^a   Gorny, Jennifer M ^a   Fujimoto, James M ^a  

^a CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Heroin antinociception; Receptor selectivity change; Streptozotocin; and opioid

Indexed keywords

7 BENZYLIDENENALTREXONE; DELTA OPIATE RECEPTOR; DIAMORPHINE; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; MORPHINE; MORPHINE 6 ACETATE; MU OPIATE RECEPTOR; NALOXONAZINE; OPIATE ANTAGONIST; RECEPTOR SUBTYPE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG SELECTIVITY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; STREPTOZOCIN DIABETES; TAIL FLICK TEST;

EID: 0032421376     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.78.443     Document Type: Article

References (39)

1. Way EL and Adler TK: The pharmacologic implications of the fate of morphine and its surrogates. Pharmacol Rev 12, 383-446 (1960)
2. Way EL: Brain uptake of morphine: Pharmacolgical implications. Fed Proc 26, 1115-1118 (1967)
3. Inturrisi CE, Max MB, Foley KM, Schultz M, Shin S-U and Houde RW: The pharmacokinetics of heroin in patients with chronic pain. N Engl J Med 310, 1213-1217 (1984)
4. Rady JJ, Roerig SC and Fujimoto JM: Heroin acts on different opioid receptors than morphine in Swiss Webster and ICR mice to produce antinociception. J Pharmacol Exp Ther 256, 448-457 (1991)
5. Rady JJ, Takemori AE, Portoghese PS and Fujimoto JM: Supraspinal delta receptor subtype activity of heroin and 6-monoacetylmorphine in Swiss Webster mice. Life Sci 55, 603-609 (1994)
6. Rady JJ, Aksu F and Fujimoto JM: The heroin metabolite, 6-monoacetylmorphine, activates delta opioid receptors to produce antinociception in Swiss Webster mice. J Pharmacol Exp Ther 266, 1222-1231 (1994)
7. Takemori AE and Portoghese PS: Selective naltrexone-derived opioid receptor antagonists. Annu Rev Pharmacol Toxicol 32, 239-269 (1992)
8. Zaki PA, Bilsky EJ, Evans CJ and Porreca F: Opioid receptor types and subtypes: The δ receptors as a model. Annu Rev Pharmacol Toxicol 36, 379-401 (1996)
9. Kamei J, Iwamoto Y, Misawa M, Nagase H and Kasuya Y: Streptozotocin-induced diabetes selectively enhances antinociception mediated by delta 1- but not delta 2-opioid receptors. Life Sci 55, PL121-PL126 (1994)
10. Kamei J, Iwamoto Y, Hitosugi H, Misawa M, Nagase H and Kasuya Y: Streptozotocin-induced diabetes selectively reduces antinociception mediated by mu 1-opioid receptors, but not that mediated by mu 2-opioid receptors. Neurosci Lett 165, 141-143 (1994)
11. Kamei J, Kawashima N and Kasuya Y: Role of spleen or spleen products in the deficiency in morphine-induced analgesia in diabetic mice. Brain Res 576, 139-142 (1992)
12. Simon GS and Dewey WL: Narcotics and diabetes. I. The effects of streptozotocin-induced diabetes on the antinociceptive potency of morphine. J Pharmacol Exp Ther 218, 318-323 (1991)
13. Brase DA, Han Y-H and Dewey WL: Effects of glucose and diabetes on binding of naloxone and dihydromorphine to opiate receptors in mouse brain. Diabetes 36, 1173-1177 (1987)
14. Rossi GC, Brown GP, Leventhal L, Yang K and Pasternak GW: Novel receptor mechanism for heroin and morphine-6,9-glucuronide analgesia. Neurosci Lett 216, 1-4 (1996)
15. Vaught JL and Takemori AE: Differential effects of leucine and methionine enkephalin on morphine-induced analgesia, acute tolerance and dependence. J Pharmacol Exp Ther 298, 89-90 (1979)
16. Vaught JL, Rothman RB and Westfall TC: Mu and delta receptors: Their role in analgesia and in the differential effects of opioid peptides in analgesia. Life Sci 30, 1443-1455 (1982)
17. Rothman RB, Long JB, Bykov V, Jacobson AE, Rice KC and Holaday JW: Beta-FNA binds irreversibly to the opiate receptor complex: In vitro and in vivo evidence. J Pharmacol Exp Ther 247, 405-416 (1988)
18. 5]enkephalin. Eur J Pharmacol 165, 1-16 (1989)
19. Jiang Q, Mosberg HI and Porreca F: Modulation of the potency and efficacy of mu-mediated antinociception by delta agonists in the mouse. J Pharmacol Exp Ther 254, 683-689 (1990)
20. Porreca F, Takemori AE, Sultana M, Portoghese PS, Bowen WD and Mosberg HI: Modulation of μ-mediated antinociception in the mouse involves opioid delta-2 receptors. J Pharmacol Exp Ther 263, 147-152 (1992)
21. 5]enkephalin-induced analgesia. Eur J Pharmacol 324, R1-R3 (1997)
22. Rossi GC, Pasternak GW and Bodnar RJ: Mu and delta opioid synergy between the periaqueductal gray and the rostro-ventral medulla. Brain Res 665, 85-93 (1991)
23. D'Amour FE and Smith DL: A method for determining loss of pain sensation. J Pharmacol Exp Ther 72, 74-79 (1941)
24. Dewey WL, Harris LS, Howes JF and Nuite JA: The effect of various neurohormonal modulators on the activity of morphine and the narcotic antagonists in the tail flick and phenylquinone test. J Pharmacol Exper Ther 175, 435-442 (1970)
25. Haley TJ and McCormick WG: Pharmacological effects produced by intracerebral injections of drugs in the conscious mouse. Br J Pharmacol 12, 12-15 (1957)
26. Pick CG, Nejat RJ and Pasternak GW: Independent expression of two pharmacologically distinct supraspinal mu analgesic systems in genetically different mouse strains. J Pharmacol Exp Ther 265, 166-171 (1993)
27. Pick CG, Paul D and Pasternak GW: Comparison of naloxonazine and β-funaltrexamine antagonism of μ1 and μ2 opioid actions. Life Sci 48, 2005-2011 (1991)
28. Steel RGD and Torrie JH: Principles and Procedures of Statistics With Special Reference to the Biological Sciences. pp 99-111, McGraw-Hill Book Company Inc, New York (1960)
29. Litchfield JT and Wilcoxon F: A simplified method for evaluating dose-effect experiments. J Pharmacol Exp Ther 96, 99-113 (1949)
30. 1-opioid receptor antagonist: 7-benzylidenenaltrexone. Eur J Pharmacol 218, 195-196 (1992)
31. Portoghese PS, Sultana M, Nagase H and Takemori AE: Application of the message-address concept in the design of highly potent and selective non-peptide δ opioid receptor antagonists. J Med Chem 31, 281-282 (1988)
32. Schuller AGP, King M, Zhang J, Czick M, Unterwald E, Pasternak GW and Pintar JE: Heroin and M6G analgesia are retained in mu opioid receptor deficient mice. Soc Neurosci Abst 23, 235.6 (1997)
33. Brown GP, Yang K, King MA, Rossi GC, Leventhal L, Chang A and Pasternak GW: Selective blockade of heroin but not traditional mu, delta, and kappa analgesia by 3-methoxynaltrexone. Soc Neurosci Abstr 23, 235.7 (1997)
34. 5 (DAMGO) and morphine-induced antinociception in mice. J Pharmacol Exp Ther 256, 890-896 (1991)
35. Kamei J, Kawashima N and Kasuya Y: Role of spleen or spleen products in the deficiency in morphine-induced analgesia in diabetic mice. Brain Res 576, 139-142 (1992)
36. Kamei J, Kawashima N, Suzuki T, Misawa M and Kasuya Y: The effects of cyclosporine on morphine-induced antinociception in diabetic mice. Neursoci Lett 158, 213-216 (1993)
37. Raffa RB, Mathiasen JR, Kimball ES and Vaught JL: The combined immunological and antinociceptive defects of beige-J mice: The possible existence of a "μ-repressin". Life Sci 52, 1-8 (1993)
38. Raffa RB, Kimball ES and Mathiasen JR: The analgesic deficit of C57BL/6J-bgJ/bgJ (Beige-J; Chediak-Higashi syndrome) mice transmitted by adoptive transfer of spleen cells to normal littermates. Life Sci 42, 1231 -1236 (1988)
39. Roerig SC and Fujimoto JM: Morphine antinociception in different strains of mice: Relationship of supraspinal multiplicative interaction to tolerance. J Pharmacol Exp Ther 247, 603-608 (1988)